John Clerici is a founding Principal of Tiber Creek Partners. For over two decades, John has been at the forefront in the creation of the public health preparedness sector, including helping large pharmaceutical and emerging biotechnology companies develop creative approaches to access non-dilutive capital to fund the development of biotechnology for emerging disease and engineered threats. Since 1999, John has assisted over three dozen companies in obtaining nearly $4 billion in funding for research, development and procurement of public health countermeasures to the Federal government, including the majority of the awards made under Project Bioshield, the U.S. Government’s initiative for preparing the Nation against a bioterrorist attack.
In 2005, John played a substantial role in the drafting and passage of the Public Readiness and Emergency Preparedness Act (PREP Act), landmark legislation that provides substantial liability protections for makers and distributors of pandemic, epidemic, and bioterrorism countermeasures. John testified as an expert in support of this legislation on four occasions before the United States Senate Appropriations Committee, HELP Committee, and Judiciary Committee.
In 2006, John was instrumental in the passage of legislation creating the Biomedical Advanced Research and Development Authority (BARDA), which builds upon and improves Project BioShield. John’s expertise in the area of public health preparedness has been recognized by leading news outlets such as the Wall Street Journal, Business Week, the Associated Press, the Boston Globe, and The Hill. He has also appeared live on the Fox News Channel as a bioterrorism expert.
Prior to joining the firm, John was a judge advocate with the U.S. Air Force where, among other assignments, he advised the Air Force Research Laboratory on the procurement of technology from research institutions throughout the United States, Europe and Asia. John has appeared as a military law analyst for the Fox News Channel and MSNBC before national audiences.
John earned his Juris Doctor from the University of North Carolina at Chapel Hill. He did his undergraduate work at the Catholic University of America, graduating summa cum laude.
Laura Smart is a founding Principal of Tiber Creek Partners, LLC. Prior to joining Tiber Creek Partners, Laura was a Policy Advisor for McKenna Long & Aldridge LLP. Before joining MLA, Laura worked as a Management Analyst at the office of Global Health Affairs, Department of Health and Human Services. While at HHS, she focused on international affairs, specifically on health issues of immediate concern, including pandemic influenza.
A native of Texas, Laura received her B.A. in Political Sciences and International Studies from Stephen F. Austin State University and her M.A. in Political Science from George Mason University.
David Noll is Senior Vice President at Tiber Creek Partners, LLC. Over the last 15 years, David has worked at the intersection of national, international and commercial efforts to ensure the successful research, development and fielding of public health countermeasures. Before joining Tiber Creek, David worked at Bavarian Nordic for seven years. There he led efforts to expand the use of the MVA-BN vaccine platform, securing over $30M in new contracts with the Department of Homeland Security, Department of Defense, and Department of Health and Human Services. Additionally, David led the evaluation program that resulted in a licensing and collaboration agreement with Janssen Pharmaceuticals for the development of a therapeutic HPV vaccine.
In 2007, David served on the staff of the National Biodefense Science Board, a Federal Advisory Committee, whose mission was to provide expert advice to the Assistant Secretary for Response and Preparedness (ASPR) on technical and scientific challenges associated with development of medical countermeasures. Prior to this David was an American Chemical Society Congressional Fellow where he served as a scientific and technical advisor to the Senate Health Education Labor and Pensions (HELP) Committee under Chairman Edward Kennedy. David participated in the NIH reauthorization, passage of the Pandemic and All-Hazards Preparedness Act, and drafting of the Biologics Price Competition and Innovation Act of 2007.
David received his Ph.D. in biochemistry from the Bloomberg School of Public Health at Johns Hopkins University and a B.A. from Boston College.
Jennifer Schneider is a Strategic Advisor to Tiber Creek Partners, LLC. Jennifer has more then a decade of experience working with companies, universities, and non-governmental organizations in London, Peru, Trinidad, Venezuela, and the United States. Prior to joining Tiber Creek, Jennifer served as a Managing Scientific Director for McKenna Long & Aldridge and was a senior researcher with Thomson Medstat, a national healthcare intelligence and research company. At Thomson Medstat, she was involved in the implementation and evaluation of epidemiological studies. Jennifer has extensive experience working in the areas of infectious disease control and policy, vector/virus interactions and viral transmission patterns.
Jennifer received her Ph.D. in biology from the University of Notre Dame. She received her M.P.H. in epidemiology and international health from the University of Michigan. Jennifer did her undergraduate studies at the University of Kansas, earning a B.A. in biology and a B.S.E. in community health education.